½ÃÀ庸°í¼
»óÇ°ÄÚµå
1444513
¼¼°èÀÇ ¿þ¾î·¯ºí ÀÇ·á±â±â ½ÃÀå : Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Wearable Medical Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
¿þ¾î·¯ºí ÀÇ·á±â±â(Wearable Medical Devices) ½ÃÀå ±Ô¸ð´Â 2024³â 417¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 862¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø±â°£(2024-2029³â) µ¿¾È 15.60%ÀÇ CAGR·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
¿þ¾î·¯ºí ±â±â´Â Çʼö »ýü ½ÅÈ£¸¦ ÀÓ»ó Áõ»ó°ú ÅëÇÕÇÏ¿© ƯÁ¤ ÁúȯÀ» ¿¹ÃøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. µû¶ó¼ COVID-19 ÅðÄ¡¸¦ À§ÇØ ¿þ¾î·¯ºí µð¹ÙÀ̽ºÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù¿¡´Â ¿þ¾î·¯ºí µð¹ÙÀ̽º°¡ ¼öÁýÇÏ´Â ¹æ´ëÇÑ µ¥ÀÌÅ͸¦ ÅëÇØ ¹ÙÀÌ·¯½ºÀÇ ¹ßº´ ¿©ºÎ¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ´ÂÁö¿¡ ´ëÇÑ ¿¬±¸°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, 2022³â 7¿ù NCBI¿¡ ¹ßÇ¥µÈ ¿¬±¸¿¡ µû¸£¸é ½º¸¶Æ®¿öÄ¡³ª ÇÇÆ®´Ï½º Æ®·¡Ä¿, ÀÇ·á ±â±â µî 22°¡Áö À¯ÇüÀÇ ¿þ¾î·¯ºí ±â¼ú µð¹ÙÀ̽º°¡ COVID-19 °¨¿°À» ½Äº°ÇÏ´Â µ¥ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ÆÒµ¥¹Í ±â°£ µ¿¾È ¿þ¾î·¯ºí ÀÇ·á ±â±âÀÇ ´ë´ëÀûÀΠäÅÃÀº ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ÆÒµ¥¹Í ÀÌÈÄ¿¡´Â ÁÖ¿ä °Ç° ÁöÇ¥¸¦ ÃßÀûÇϱâ À§ÇÑ ¿þ¾î·¯ºí µð¹ÙÀ̽ºÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀåÀÌ ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿þ¾î·¯ºí ÀÇ·á ±â±â ½ÃÀåÀº ȯÀÚ»Ó¸¸ ¾Æ´Ï¶ó ÀϹÝÀÎÀÇ ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» °³¼±ÇÒ ¼ö ÀÖ´Â ±â¼ú Çõ½Å°ú ¹ßÀüÀ¸·Î ÀÎÇØ ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ±â¼úÀº ´Ù¾çÇÑ ÀÇ·á ¼Ö·ç¼ÇÀ» ÅëÇØ »ý¸®Àû Áõ»óÀ» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â Æí¸®ÇÑ ¸ðµå¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â ¼ÒºñÀÚ°¡ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó Àǻ簡 ºÐ¼®ÇÒ ¼ö ÀÖ´Â ½Ç½Ã°£ µ¥ÀÌÅ͵µ Á¦°øÇÕ´Ï´Ù. Apple WatchÀÇ ½ÉÀüµµ ±â´ÉºÎÅÍ »õ·Î¿î ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡ À̸£±â±îÁö ¿þ¾î·¯ºí ÀÇ·á ±â¼úÀº ÀÇ·á »ê¾÷¿¡¼ Æø³Ð°Ô È°¿ëµÉ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» Áö´Ï°í ÀÖ½À´Ï´Ù.
ÁÖ¿ä ½ÃÀå Ç÷¹À̾îµéÀÇ ¿þ¾î·¯ºí ±â±â Ãâ½Ã°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖ¿ä °Ç° ÁöÇ¥¸¦ ¸ð´ÏÅ͸µÇϱâ À§ÇØ ÀÌ·¯ÇÑ ±â±âÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 8¿ù, GOQii´Â û¼Ò³â°ú û³âÃþÀ» °Ü³ÉÇÑ ½º¸¶Æ® ¹ÙÀÌÅ» ¿ïÆ®¶ó ¹× GOQii ½ºÆ®¸² µð¹ÙÀ̽º¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ µÎ Á¦Ç°Àº ¼ÒºñÀÚ°¡ ÀÚ½ÅÀÇ ¹ÙÀÌÅ»À» ½±°Ô ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.
¶ÇÇÑ È°·Â ¡Èĸ¦ ÃøÁ¤Çϱâ À§ÇØ ¿þ¾î·¯ºí ÀåÄ¡¿¡ Àΰø Áö´É (AI) ±â¼úÀ» ±¸ÇöÇÏ´Â °Í°ú °°Àº Çõ½ÅÀûÀÎ ±â¼úÀ» äÅÃÇϱâÀ§ÇÑ ±â¾÷ÀÇ ÀÚ±Ý Á¶´ÞÀº ±â¼úÀûÀ¸·Î Áøº¸ µÈ Á¦Ç°ÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÁÖµµ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù Respira Labs´Â À½Çâ °ø¸íÀ» »ç¿ëÇÏ¿© Æó ±â´ÉÀ» Æò°¡ÇÏ°í Æó °ø±â·®ÀÇ º¯È¸¦ ÆľÇÇÏ´Â ÈäºÎ ¿þ¾î·¯ºíÀ» Áö¼ÓÀûÀ¸·Î °³¹ßÇÏ°í Á¦Á¶Çϱâ À§ÇØ 280¸¸ ´Þ·¯ÀÇ ÀÚ±Ý Á¶´Þ ¶ó¿îµå¸¦ ¸¶°¨ÇßÀ¸¸ç, ÀÌ´Â COPD, COVID-19 ¹× õ½Ä ȯÀÚ¿¡°Ô ƯÈ÷ Áß¿äÇÕ´Ï´Ù.
±×·¯³ª °³¹ßµµ»ó±¹ ¹× Àú°³¹ß±¹¿¡¼´Â ÀϺΠ¿þ¾î·¯ºí ±â±â¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·°ú ¿þ¾î·¯ºí ±â±âÀÇ ³ôÀº °¡°Ý µî ¿äÀÎÀÌ ½ÃÀå ¼ºÀå Àü¸ÁÀÇ ÁÖ¿ä °úÁ¦ Áß ÀϺÎÀÔ´Ï´Ù.
¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) µµÀÔÀº Ç÷¾Ð ¹× Ç÷´çÄ¡¿Í °°Àº Áß¿äÇÑ À§Çè ÁöÇ¥¸¦ ÃøÁ¤ÇÔÀ¸·Î½á ¸¸¼º ÁúȯÀÇ °ü¸®¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. RPMÀº Àå±â ÀÔ¿ø °¨¼Ò, °Ç° °ü¸® ºñ¿ë Àý°¨, ÀÇ»ç ¿¹¾à °¨¼Ò µî º´¿ø ¹× ÃÖÁ¾ »ç¿ëÀÚ¿¡°Ô ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ÀÌ°ÍÀº ¸¸¼º ÁúȯÀÇ Ä¡·á¿Í °ü·ÃµÈ ºñ¿ëÀ» ÁÙÀÌ´Â µ¥µµ µµ¿òÀÌ µË´Ï´Ù.
¸¸¼º ÁúȯÀ» °¡Áø »ç¶÷µé Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡´Â ¼¼°è¿¡¼ RPM ¼ºñ½ºÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¿µ±¹ ½ÉÀåÀç´Ü¿¡ µû¸£¸é 2022³â 8¿ù ÇöÀç ¿µ±¹¿¡¼´Â ÇöÀç 760¸¸¸íÀÌ ½ÉÀå ¹× ¼øȯ±â ÁúȯÀ» °¡Áö°í »ì°í ÀÖ½À´Ï´Ù. ±×·¯³ª Àα¸ÀÇ °í·ÉÈ¿Í È®´ë°¡ ÁøÇàµÊ¿¡ µû¶ó ½ÉÀå ¹× ¼øȯ±â ÁúȯÀ¸·Î ÀÎÇÑ »ýÁ¸À²ÀÌ Çâ»óµÊ¿¡ µû¶ó ÀÌ·¯ÇÑ ¼öÄ¡´Â °è¼Ó »ó½ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼±Áø±¹¿¡¼ ¸¸¼º ÁúȯÀÇ ÀÌȯÀ²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÏ°í ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Çõ½ÅÀûÀÎ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â¸¦ ½ÃÀå¿¡ ÅõÀÔÇϱâ À§ÇÑ ³ë·Â Áõ°¡·Î ÀÌ ºÎ¹® ½ÃÀå ¼ºÀåÀÌ ´õ¿í ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î BioIntelliSence´Â 2022³â 3¿ù¿¡ ¿ø°Ý ȯÀÚ °ü¸®¸¦ À§ÇÑ ÀÇ·á µî±Þ ÃæÀü½Ä ¿þ¾î·¯ºí µð¹ÙÀ̽º BioButtonÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÀåÄ¡´Â 20°³ ÀÌ»óÀÇ ±¤¹üÀ§ÇÑ »ýü »çÀÎ ¹× »ý¸®ÇÐÀû »ýü ÀÎÁõ ´ÙÁß ¸Å°³º¯¼öÀÇ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
µû¶ó¼, »ó±â ¿äÀο¡ ÀÇÇØ ÀÌ ºÎ¹®Àº ¿¹Ãø ±â°£À» ³Ñ¾î ÃßÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì´Â ¿þ¾î·¯ºí ÀÇ·á±â±â ½ÃÀå Àüü¿¡¼ Å« Á¡À¯À²À» ÀâÀ» °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖÀ¸¸ç, ¹Ì±¹ÀÌ ½ÃÀå¿¡ ÁÖ¿ä °øÇå±¹À¸·Î ºÎ»óÇÏ°í ÀÖ½À´Ï´Ù.
¹Ì±¹Àº ½ÉÇ÷°üÁúȯ°ú »ýÈ°½À°üº´ÀÇ ÀÌȯÀ² Áõ°¡, ¿þ¾î·¯ºí ÀÇ·á±â¼úÀÇ Ã¤Åà Áõ°¡, 1Àδç ÀÇ·áºñÀÇ ³ôÀÌ µîÀ¸·Î ¿þ¾î·¯ºí ÀÇ·á±â±â ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Garmin Ltd, Fitbit Inc., Biotelemetry Inc. µî ÁÖ¿ä ±â¾÷ÀÇ °·ÂÇÑ ¹ßÆÇÀÌ ¹Ì±¹¿¡ ÁýÁߵǾî Çõ½ÅÀûÀÎ ¿þ¾î·¯ºí ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇØ ¿Ô½À´Ï´Ù.
¹Ì±¹¿¡¼ ¿þ¾î·¯ºí ÀÇ·á±â±â ÆǸſ¡ ´ëÇÑ ÆÄÆ®³Ê½ÊÀÌ Áõ°¡ÇÔ¿¡ µû¶ó äÅà Áõ°¡·Î ÀÌ Áö¿ªÀÇ ÀÌ ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù, ¸ÞµåÆ®·Î´Ð plc´Â ¹Ì±¹ÀÇ µ¶Á¡Àû º´¿ø°ú Áö¼ÓÀûÀÎ ¿¬°áµÈ ¸ð´ÏÅ͸µÀ» À§ÇÑ ´ÙÁß ¸Å°³º¯¼ö ¿þ¾î·¯ºí BioButtonÀÇ ±Þ¼º±â ÈÄ º´¿ø¿¡¼ °¡Á¤À¸·ÎÀÇ 30ÀÏ ¹èÆ÷±Ç¿¡ ´ëÇØ, BioIntelliSense¿Í Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ü°áÇß½À´Ï´Ù.
°Ô´Ù°¡ FDA¿¡ ÀÇÇÑ ¿þ¾î·¯ºí µð¹ÙÀ̽ºÀÇ ½ÂÀÎ Áõ°¡¿¡ µû¶ó ½ÃÀå ±â¾÷¿¡ ÀÇÇÑ Çõ½ÅÀûÀÎ µð¹ÙÀ̽ºÀÇ °³¹ß·Î ½ÃÀåÀÇ ¼ºÀåÀÌ ´õ¿í ±Þ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 6¿ù¿¡ FDA°¡ ½ÂÀÎÇÑ MedicalgorithmicsÀÇ ECG ¿þ¾î·¯ºí À¯´Ö, Qpatch. ÀÌ ECG ¿þ¾î·¯ºí µð¹ÙÀ̽º´Â °³º° ECG ½ÅÈ£¸¦ ÃøÁ¤ÇÏ°í ÃÖ´ë 15ÀÏÀÇ ¸ð´ÏÅ͸µ ¼¼¼Ç¿¡¼ Á¤È®ÇÑ ºÎÁ¤¸Æ Áø´ÜÀ» ¾òÀ» ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀο¡ µû¶ó ºÏ¹Ì´Â ±â¼úÀûÀ¸·Î ÁøÇàµÈ ¿þ¾î·¯ºí ÀÇ·á±â±âÀÇ Ã¤Åà Áõ°¡, ÇコÄɾî ÁöÃâ Áõ°¡, ÁÖ¿ä ½ÃÀå±â¾÷ÀÇ À̴ϼÅƼºê Áõ°¡·Î »ó´çÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿þ¾î·¯ºí ÀÇ·á±â±â ½ÃÀåÀº ½ÃÀå¿¡¼ È°µ¿ÇÏ´Â ¸¹Àº ±â¾÷ÀÇ Á¸Àç¿¡ ÀÇÇØ ¼¼ºÐȵǰí ÀÖ½À´Ï´Ù. ½ÃÀåÀº ƯÈ÷ ±â¾÷¿¡ ÀÇÇÑ Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã, ±â¼ú Áøº¸, ½ÅÈï ½Å½ÃÀå ±â¾÷¿¡ ÀÇÇØ ¿òÁ÷ÀÔ´Ï´Ù. ÀÌ ½ÃÀå¿¡¼ È°µ¿ÇÏ´Â ½ÃÀå ±â¾÷¿¡´Â Fitbit, Lifesense, Apple, Omron Corporation, Samsung, Philips µîÀÌ Æ÷ÇԵ˴ϴÙ.
The Wearable Medical Devices Market size is estimated at USD 41.75 billion in 2024, and is expected to reach USD 86.20 billion by 2029, growing at a CAGR of 15.60% during the forecast period (2024-2029).
Wearable devices play a crucial role in predicting certain disorders by integrating essential vital signs with clinical symptomology. The use of wearable devices in a bid to combat COVID-19 has therefore been ramped up. Research has recently expanded on whether the extensive data that wearable devices collect can predict the onset of the virus or not.
For instance, according to a study published in NCBI in July 2022, 22 distinct types of wearable technology devices, such as smartwatches or fitness trackers, medical devices, and others, are utilized to identify COVID-19 infections. Such a huge adoption of wearable medical devices during the pandemic has been expected to drive market growth. Furthermore, post-pandemic, the market is expected to drive swiftly due to the rise in the adoption of wearable devices to track key health indicators.
The wearable medical devices market is growing at a faster pace owing to the rising technological innovations and advancements, as they can improve the lifestyle of the general population as well as the patient population. Wearable technologies offer a convenient mode of monitoring physiological symptoms, featuring a multitude of medical solutions. These devices are not only easy for consumer use but also offer real-time data for physicians to analyze. From the Apple Watch's EKG capabilities to new continuous glucose monitoring systems, wearable medical technologies have a broad range of potential applications in the healthcare industry.
The rise in the launch of wearable devices by the key market players is expected to propel market growth due to the rise in the adoption of such devices to monitor key health indicators. For instance, in August 2022, GOQii launched Smart Vital Ultra and GOQii Stream devices targeted at young adults and youth. These two products help enable consumers to monitor their vitals with ease.
Also, fundraising by companies to adopt innovative technologies such as implementing artificial intelligence (AI) technology in a wearable device to measure vital signs are anticipated to drive the market growth over the forecast period due to the rise in adoption of the technologically advanced product. For instance, in February 2022, Respira Labs closed a USD 2.8 million financing round to continue developing and manufacturing its chest wearable that uses acoustic resonance to assess lung function and identify changes in lung air volume, which is especially important for COPD, COVID-19, and asthma patients.
However, factors such as the lack of awareness about the availability of some wearable devices in developing and underdeveloped countries and the high cost of wearable devices are some of the major challenges to the growth prospects of the market.
The implementation of Remote Patient Monitoring (RPM) may improve the management of chronic disorders by measuring critical risk indicators, such as blood pressure and glucose. RPM has several advantages for hospitals and end users, such as a reduction in extended hospitalization, a low cost of healthcare, and fewer doctor appointments. This can also help lower the costs associated with the treatment of chronic disorders.
The increase in the number of people with chronic disorders and the rising elderly population are the major factors boosting the growth of RPM services across the globe. According to the British Heart Foundation, in August 2022, in the UK, there are currently 7.6 million people living with heart and circulatory diseases. However, as the population ages and expands and as survival rates from heart and circulatory events improve, these numbers may continue to rise. Such a high prevalence of chronic diseases in developed countries is anticipated to further increase the demand for remote patient monitoring devices, driving this segment's growth.
Furthermore, the rise in initiatives from the key market players to launch their innovative remote patient monitoring devices in the market is anticipated to bolster the market growth of this segment further. For instance, in March 2022, BioIntelliSence launched a medical-grade BioButton rechargeable wearable device for remote patient care. The device allows for continuous multi-parameter monitoring of a broad range of 20+ vital signs and physiologic biometrics.
Therefore, owing to the above-mentioned factors, this segment is expected to drive over the forecast period.
North America is expected to hold a significant share of the overall wearable medical devices market, with the United States emerging as the major contributor to the market.
The United States holds the largest share in the wearable medical devices market due to the high prevalence of cardiovascular and lifestyle-related diseases and increased adoption of wearable medical technology, along with high per capita medical expenditure. Additionally, the strong foothold of major players such as Garmin Ltd, Fitbit Inc., and Biotelemetry Inc. are concentrated in the United States and have been investing in the research and development of innovative wearables.
Rising partnerships for the distribution of wearable medical devices in the United States are expected to drive the growth of this market in this region due to the rise in adoption. For instance, in April 2022, Medtronic plc entered into a strategic partnership with BioIntelliSense for the exclusive United States hospital and 30-day post-acute hospital-to-home distribution rights of the BioButton multi-parameter wearable for continuous, connected monitoring.
Furthermore, the rise in approval of wearable devices by the FDA is further expected to surge the market growth due to the development of innovative devices from the market players. For instance, in June 2022. the FDA-approved Medicalgorithmics' ECG wearable unit, Qpatch. This ECG wearable device has been designed to measure individual ECG signals and obtain accurate cardiac arrhythmia diagnoses from monitoring sessions of up to 15 days.
Therefore, owing to the above-mentioned factors, the North American region is expected to show significant growth due to the rise in the adoption of technologically advanced wearable medical devices, the rise in healthcare expenditure, and the rise in initiatives from the key market players.
The wearable medical devices market is fragmented due to the presence of many players operating in the market. The market is driven by the launch of innovative products by the players, technological advancements, and emerging new market players, among others. Some of the market players operating in this market include Fitbit, Lifesense, Apple, Omron Corporation, and Samsung, Philips, among others.